Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001193125-26-054779·Bain Capital Life Sciences Fund, L.P.
Schedule 13G ownership disclosure
X4 Pharmaceuticals Inc
Common Stock, par value $0.001 per share · CUSIP: 98420X202
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Bain Capital Life Sciences Fund, L.P.
Shares: 0 · Class: 0%
- Bain Capital Life Sciences Fund II, L.P.
Shares: 64,190 · Class: 0.07%
- BCIP Life Sciences Associates, LP
Shares: 7,817 · Class: 0.01%
- BCLS II Investco, LP
Shares: 758,598 · Class: 0.8%
- BCLS I Investco, LP
Shares: 89,633 · Class: 0.09%
- BCLS II Equity Opportunities, LP
Shares: 7,047,216 · Class: 7.43%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-054779
- Form type
- SCHEDULE 13G/A
- Filer
- Bain Capital Life Sciences Fund, L.P.
- CIK
- CIK 1687968
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership